FDA Accepts BLA Resubmission of Cosibelimab for the Treatment of Advanced cSCC
The U.S. Food and Drug Administration (FDA) has accepted for review Checkpoint’s resubmission of its Biologics License Application (BLA) for cosibelimab, its anti-programmed death ligand-1 (PD-L1) antibody, as a potential new treatment for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or curative radiation. The […]